Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Stage IV or recurrent non-small cell lung cancer (NSCLC)~* Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor receptor (EGFR), (except T790M single mutation only)~* Measurable disease (at least one lesion \>= 10 mm in longest diameter)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Patients with T790M single mutation only~* Prior exposure to agents directed at the human epidermal receptor (HER) axis, e.g. erlotinib, gefitinib, cetuximab, trastuzumab~* Prior chemotherapy or systemic anti-cancer therapy for advanced NSCLC disease~* Symptomatic or uncontrolled central nervous system (CNS) metastases~* Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal or squamous cell carcinoma of the skin, or surgically treated localized prostate cancer, or surgically treated ductal cell carcinoma in situ of the breast~* Any significant ophthalmologic abnormality~* Pre-existing parenchymal lung disease such as pulmonary fibrosis~* Use of coumarins (for anti-coagulation therapy the use of low molecular weight heparin is recommended instead)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib 150 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).